{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:44Z","timestamp":1782276464877,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019823","name":"University of Maryland, Baltimore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-EB028534"],"award-info":[{"award-number":["R01-EB028534"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbrc.2026.153430","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:26:21Z","timestamp":1770654381000},"page":"153430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An effective tumor-inhibiting siRNA delivery platform"],"prefix":"10.1016","volume":"807","author":[{"given":"Qixin","family":"Leng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. James","family":"Mixson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153430_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/cgt.2011.40","article-title":"Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo","volume":"18","author":"Chou","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbrc.2026.153430_bib2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/acs.biochem.4c00650","article-title":"Ionic coating of siRNA polyplexes with cRGD-PEG-Hyaluronic acid to modulate serum stability and in vivo performance","volume":"64","author":"Vetter","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2026.153430_bib3","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.3390\/molecules29235541","article-title":"A facile and promising delivery platform for siRNA to solid tumors","volume":"29","author":"Leng","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2026.153430_bib4","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.153430_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-022-01501-7","article-title":"Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS\/MAPK pathway activation","volume":"24","author":"Tang","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbrc.2026.153430_bib6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/bjc.2014.49","article-title":"Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1","volume":"110","author":"Akashi","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.153430_bib7","first-page":"349","article-title":"NRP1-positive lung cancer cells possess tumor-initiating properties","volume":"39","author":"Jimenez-Hernandez","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2026.153430_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1084\/jem.20111424","article-title":"Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth","volume":"209","author":"Hamerlik","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.153430_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/path.2989","article-title":"Neuropilin-1 expression in cancer and development","volume":"226","author":"Jubb","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbrc.2026.153430_bib10","first-page":"5399","article-title":"PD-L1 expression levels on tumor cells affect their immunosuppressive activity","volume":"18","author":"Zheng","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbrc.2026.153430_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-4939-9220-1_12","article-title":"Targeting cancer with peptide RNAi nanoplexes","volume":"1974","author":"Mixson","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbrc.2026.153430_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/cgt.2008.29","article-title":"Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts","volume":"15","author":"Leng","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbrc.2026.153430_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1042\/BST20200485","article-title":"Inhibition of RAF dimers: it takes two to tango","volume":"49","author":"Cook","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbrc.2026.153430_bib14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.molmed.2024.04.008","article-title":"PD-L1 at the crossroad between RNA metabolism and immunosuppression","volume":"30","author":"Arthur","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbrc.2026.153430_bib15","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.32604\/or.2025.061637","article-title":"Tumor-expressing PD-L1 regulates NT5E expression through MAPK\/ERK pathway in triple-negative breast cancer","volume":"33","author":"Cheng","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bbrc.2026.153430_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122868","article-title":"An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment","volume":"14","author":"Sharifi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.153430_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/0008-5472.CAN-12-2071","article-title":"Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors","volume":"73","author":"Huo","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.153430_bib18","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1038\/ncomms5904","article-title":"An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability","volume":"5","author":"Pang","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.153430_bib19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.153430_bib20","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2217\/nnm-2017-0107","article-title":"iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery","volume":"12","author":"Ma","year":"2017","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.bbrc.2026.153430_bib21","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1007\/s00432-021-03694-4","article-title":"Inhibitors of PD-1\/PD-L1 and ERK1\/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines","volume":"147","author":"Br\u00e4utigam","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.153430_bib22","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated antitumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.153430_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113285","article-title":"The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy","volume":"12","author":"Quatrini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.153430_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118268","article-title":"Comparative druggability of PD-1\/PD-L1 inhibitors (A56, HD10): cross-species differences in PD-L1 exposure and efficacy","volume":"128","author":"Awadasseid","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.153430_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102734","article-title":"siRNA nanoparticle targeting PD-L1 activates tumor immunity and abrogates pancreatic cancer growth in humanized preclinical model","volume":"10","author":"Jung","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2026.153430_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152773","article-title":"Systemic dual delivery of a tumor-inhibiting plasmid expressing p16 and shRaf","volume":"787","author":"Leng","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:08:45Z","timestamp":1782274125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S0006291X26001944"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153430","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An effective tumor-inhibiting siRNA delivery platform","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153430"}}